Chang Che-Wei, Yin Hsin-Ling, Li Ching-Chia
Department of Urology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Urol Ann. 2021 Oct-Dec;13(4):434-437. doi: 10.4103/UA.UA_187_20. Epub 2021 Sep 2.
Clear cell adenocarcinoma (CCA) rarely occurs in men, not to mention in prostate. We reported a 44-year-old male patient who suffered from recurrent dysuria and frequency for 6 months. Transurethral resection of the prostate was performed to relieve bladder outlet obstruction. However, CCA of the prostate was confirmed through pathological examination. A thorough checkup was performed to distinguish it from metastatic clear cell carcinoma from other primary origins. Currently, no consensus for the treatment of CCA of the prostate has been reached. After discussing with the patient, he decided to receive immunotherapy with pembrolizumab. Herein, we reported this rare case of CCA in the prostate.
透明细胞腺癌(CCA)在男性中很少见,更不用说发生在前列腺了。我们报告了一名44岁男性患者,他反复出现排尿困难和尿频6个月。为缓解膀胱出口梗阻,进行了经尿道前列腺切除术。然而,通过病理检查确诊为前列腺CCA。进行了全面检查以将其与其他原发部位的转移性透明细胞癌区分开来。目前,对于前列腺CCA的治疗尚未达成共识。与患者讨论后,他决定接受帕博利珠单抗免疫治疗。在此,我们报告了这例罕见的前列腺CCA病例。